Condition: Duchenne Muscular Dystrophy · Fascioscapulohumeral Muscular Dystrophy · Myotonic Dystrophy 1 · Sponsor: Centre Hospitalier Universitaire de Liege
The objective of the ActiLiège Next study is to collect longitudinal data from patients and control subjects using a wearable magneto-inertial device. By collecting natural history data in various neuromuscular disorders (Duchenne Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy, Myotonic Dystrophy 1, Charcot-Marie-Tooth, Centronuclear Myopathy, Congenital Muscular Dystrophy), we aim to validate digital outcome measures to continuously assess motor function in real-life.
This description comes directly from the study's public registry record.
Charline DUBOIS · 043215695 · charline.dubois@citadelle.be
Always discuss trial participation with your own doctor first.
| CHR de la Citadelle | Liège, Belgium | Recruiting |
| Fakultni nemocnice v Motole | Prague, Czechia | Active Not Recruiting |
| Galaa Military Medical Complex | Cairo, Egypt | Active Not Recruiting |
| Semmelweis University 2nd Department of Paediatrics | Budapest, Hungary | Active Not Recruiting |
| Warsaw Medical University Hospital, Department of Neurology | Warsaw, Poland | Active Not Recruiting |
| Pediatric Neurology Clinic, Clinical Hospital of Psychiatry "Prof. Dr. Al. Obregia" | Bucharest, Romania | Recruiting |
| National Clinical Hospital for Children Neurohabilitation "Dr Nicolae Robanescu" | Bucharest, Romania | Active Not Recruiting |
| University Children's Hospital, Department for Pediatric Neurology | Ljubljana, Slovenia | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05982119